New Class of Benzodiazepinone Derivatives as Pro-Death Agents Targeting BIR Domains in Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Inhibitor of Apoptosis Proteins (IAPs) are key targets in cancer therapy.
• IAP deregulation in the NF-κB pathway contributes to chemoresistance, even with Smac-mimetic treatments.
• FC2 was identified as a NF-κB pathway modulator targeting cIAP2 and XIAP BIR1 domains.

Purpose of the Study:

• To design and synthesize novel FC2 derivatives to improve efficacy against cancer cells.
• To evaluate the cytotoxic effects and binding affinities of FC2 derivatives against IAP targets.
• To explore the potential of FC2 derivatives in combination therapies.

Main Methods:

• Virtual screening and library design of 22 FC2 derivatives.
• Cytotoxicity assays in MDA-MB-231 adenocarcinoma cells.
• Fluorescence-based binding assays and virtual docking against cIAP2 and XIAP BIR1 domains.

Main Results:

• FC2 derivatives 4m and 4p exhibited enhanced potency and low micromolar binding affinity for cIAP2 and XIAP BIR1 domains.
• Derivatives 4b and 4u showed promising cytotoxic effects when combined with Tumor Necrosis Factor (TNF).
• These findings suggest a link between FC2 derivatives, IAP targeting, and the NF-κB pathway.

Conclusions:

• FC2 derivatives 4m and 4p represent promising candidates for IAP-targeting cancer therapies.
• The study provides a foundation for further optimization of FC2 analogs.
• Combination strategies involving FC2 derivatives and TNF show potential for overcoming chemoresistance.